Clinical Research Directory
Browse clinical research sites, groups, and studies.
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
Sponsor: OHSU Knight Cancer Institute
Summary
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2021-09-03
Completion Date
2026-09-03
Last Updated
2025-09-25
Healthy Volunteers
No
Conditions
Interventions
Biopsy
Undergo biopsy
Biospecimen Collection
Undergo collection of blood and/or tissue samples
Electronic Health Record Review
Medical records are reviewed
Locations (2)
OHSU Knight Cancer Institute
Portland, Oregon, United States
Fred Hutch
Seattle, Washington, United States